B. Braun Renal Therapies Division To Launch New Class of Kidney Dialyzer
xevonta™ to be available in September
Bethlehem, PA – September 1, 2016 – The Renal Therapies Division of B. Braun Medical Inc., announced today that it will launch xevonta™, a next generation dialyzer for the U.S. market, after recently receiving 510(k) clearance. A dialyzer is a dialysis filter and is often referred to as an “artificial kidney.” Its function is to remove the wastes and excess fluid from the blood when a patient’s kidneys can no longer perform the task.
“Our new dialyzer’s advanced membrane technology was designed to improve clearance performance by removing more toxins from a patient’s blood,” said Samuel Amory, Vice President, Renal Therapies Division at B. Braun Medical.
B. Braun has enhanced the technology of formulating the amembris fibers in xevonta by designing the filtration membrane to filter out the smaller toxin molecules in the patient’s blood, like urea and creatinine, while maintaining most of the larger blood components, like albumin and beta-2 microglobulin molecules, that are vital to a patient’s health.
Available in September, xevonta will be offered in a broad range of sizes to accommodate different patient requirements.
B. Braun has been a leader in providing the dialysis community with innovative products for more than 35 years. Its Dialog+® Hemodialysis System incorporates state-of-the art technology in dialysis. In addition, B. Braun’s dialysis product line offers a wide array of disposable products that allow healthcare professionals to tailor treatments for their patients.
As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone® dialyzers and Medisystems’ Streamline Bloodlines, the Renal Therapies Division of B. Braun is committed to the continued development of high quality products for hemodialysis and continuous renal replacement therapy supported by a team of clinical nurses, field service personnel, customer service and 24/7 technical assistance.
To learn more about xevonta, call Renal Therapies Division customer service at 800-848-2066.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is part of the B. Braun Group of Companies in the U.S., which is headquartered in Bethlehem, Pa., and includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.